> Details

Nöpel‐Dünnebacke, Stefanie; Jütte, Hendrick; Denz, Robin; Feder, Inke Sabine; Kraeft, Anna‐Lena; Lugnier, Celine; Teschendorf, Christian; Collette, Daniela; Böhner, Hinrich; Engel, Lars; Mueller, Lothar; Hartmann, Frank; Kaiser, Ulrich; Bruch, Harald‐Robert; Hollerbach, Stephan; Arnold, Dirk; Timmesfeld, Nina; Tannapfel, Andrea; Reinacher‐Schick, Anke

Causes of mortality in elderly UICC stage III colon cancer (CC) patients––Tumor‐related death and competing risks from the German AIO colorectal study group Colopredict Plus (CPP) registry

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Causes of mortality in elderly UICC stage III colon cancer (CC) patients––Tumor‐related death and competing risks from the German AIO colorectal study group Colopredict Plus (CPP) registry
  • Contributor: Nöpel‐Dünnebacke, Stefanie; Jütte, Hendrick; Denz, Robin; Feder, Inke Sabine; Kraeft, Anna‐Lena; Lugnier, Celine; Teschendorf, Christian; Collette, Daniela; Böhner, Hinrich; Engel, Lars; Mueller, Lothar; Hartmann, Frank; Kaiser, Ulrich; Bruch, Harald‐Robert; Hollerbach, Stephan; Arnold, Dirk; Timmesfeld, Nina; Tannapfel, Andrea; Reinacher‐Schick, Anke
  • imprint: Wiley, 2022
  • Published in: Cancer Medicine
  • Language: English
  • DOI: 10.1002/cam4.4540
  • ISSN: 2045-7634
  • Keywords: Cancer Research ; Radiology, Nuclear Medicine and imaging ; Oncology
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Colon cancer (CC) is a disease of elderly patients (pts.) with a median age of 73 years (yrs.). Lack of data about the effects of adjuvant chemotherapy (ACT) is caused by underrepresentation of this clinically relevant cohort in interventional trials. We analyzed real‐world data from the German CPP registry with regard to a possible benefit of ACT in elderly (70+ yrs.) versus younger pts. (50 to &lt;70 yrs.) taking cause‐specific deaths into account.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We analyzed the effect of age and ACT on overall survival (OS) and cause‐specific death of stage III pts. using Cox regression.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>In total, 1558 pts. were analyzed and follow‐up was 24.6 months. 62.6% of the elderly received ACT whereas 91.1% of younger pts. (<jats:italic>p </jats:italic>&lt; 0.001). Oxaliplatin combinations were significantly less often given to older than younger pts. (38.8% vs. 88.9%; <jats:italic>p </jats:italic>&lt; 0.001). Mean Charlson comorbidity score was significantly lower in pts. that received ACT (0.61) than in those without ACT (1.16; <jats:italic>p </jats:italic>&lt; 0.001). ACT was an independent positive prognostic factor for cancer‐related death in elderly pts. even in pts. 75+ yrs. No significant difference in the effect of ACT could be observed between age groups (interaction: cancer‐specific death HR = 1.7948, <jats:italic>p </jats:italic>= 0.1079; death of other cause HR = 0.7384, <jats:italic>p </jats:italic>= 0.6705).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>ACT was an independent positive prognostic factor for OS. There may be a cohort of elderly with less co‐morbidities who benefit from ACT.</jats:p></jats:sec>
  • Access State: Open Access